These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37634492)

  • 1. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
    Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
    Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
    Tabata S; Higuchi T; Tatsukawa S; Narimatsu K; Takeo H; Matsukuma S; Ito T
    Intern Med; 2019 Nov; 58(22):3313-3318. PubMed ID: 31292389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab.
    Iskandar A; Hwang A; Dasanu CA
    J Oncol Pharm Pract; 2019 Dec; 25(8):2016-2018. PubMed ID: 30486744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab).
    Ibrahim K; Maghfoor I; Elghazaly A; Bakshi N; Mohamed SY; Aljurf M
    Hematol Oncol Stem Cell Ther; 2011; 4(2):100-2. PubMed ID: 21727772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
    Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
    Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy.
    Yuzuriha A; Saitoh T; Koiso H; Mitsui T; Uchiumi H; Yokohama A; Handa H; Kojima M; Tsukamoto N; Karaswa M; Murakami H; Nojima Y
    Acta Haematol; 2011; 126(3):147-50. PubMed ID: 21757886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease.
    Karki NR; Arfa AS; Savage N; Kutlar A
    Acta Haematol; 2022; 145(2):214-220. PubMed ID: 34818661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
    Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
    Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentric IL-5-positive Castleman Disease With Nephrotic Syndrome Relapsed After Rituximab Treatment.
    Mima A; Lee R; Murakami A; Gotoda H; Akai R; Lee S
    In Vivo; 2023; 37(1):493-497. PubMed ID: 36593046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease.
    Kaga H; Kurahashi H; Kubota A; Hatano Y; Nanjo H; Wakui H; Takahashi N
    Int J Hematol; 2022 Jan; 115(1):129-134. PubMed ID: 34591291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K; Murayama S; Ito H; Koga T
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent HIV viral blips during two episodes of multicentric Castleman disease in an adult on antiretroviral therapy: Implication for HIV persistence.
    Darwish I; Costiniuk C; Kronfli N; Haegert D; Routy JP
    IDCases; 2021; 26():e01315. PubMed ID: 34786336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
    Ocio EM; Sanchez-Guijo FM; Diez-Campelo M; Castilla C; Blanco OJ; Caballero D; San Miguel JF
    Am J Hematol; 2005 Apr; 78(4):302-5. PubMed ID: 15795923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.